

Financial news for EBS dated on 2020-06-09: 95 Biggest Movers From Yesterday

Financial news for EBS dated on 2020-06-08: 71 Stocks Moving In Monday's Mid-Day Session

Financial news for EBS dated on 2020-06-08: Cantor Fitzgerald Maintains Overweight on Emergent BioSolutions, Lowers Price Target to \$85

Financial news for EBS dated on 2020-06-08: 33 Stocks Moving in Monday's Pre-Market Session

Financial news for EBS dated on 2020-06-02: The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To \$500M In Biotechs

Financial news for EBS dated on 2020-06-01: Stocks That Hit 52-Week Highs On Monday

Financial news for EBS dated on 2020-06-01: Emergent BioSolutions Wins a Task Order from the Department of Health & Human Services to Use its Manufacturing Infrastructure to Support the US Government's Delivery of Coronavirus Vaccines

Financial news for EBS dated on 2020-05-13: The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter

Financial news for EBS dated on 2020-05-12: Stocks That Hit 52-Week Highs On Tuesday

Financial news for EBS dated on 2020-05-12: The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands \$384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings

Financial news for EBS dated on 2020-05-11: Stocks That Hit 52-Week Highs On Monday

Financial news for EBS dated on 2020-05-06: Argus Research Maintains Buy on Emergent BioSolutions, Raises Price Target to \$90

Financial news for EBS dated on 2020-05-01: Cantor Fitzgerald Maintains Overweight on Emergent BioSolutions, Raises Price Target to \$86

Financial news for EBS dated on 2020-05-01: Chardan Capital Maintains Buy on Emergent BioSolutions, Raises Price Target to \$86

Financial news for EBS dated on 2020-05-01: Moderna, Lonza Strike Deal To Manufacture Up To 1 Billion Doses Of Coronavirus Vaccine Candidate Annually

Financial news for EBS dated on 2020-04-30: Emergent BioSolutions Sees FY20 Sales Guidance Of \$1.175B-\$1.275B

Financial news for EBS dated on 2020-04-30: Emergent BioSolutions Q1 EPS \$0.010, Inline, Sales \$192.500M Miss \$199.470M Estimate

Financial news for EBS dated on 2020-04-30: Wells Fargo Maintains Overweight on Emergent BioSolutions, Raises Price Target to \$85

Financial news for EBS dated on 2020-04-30: The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1

Financial news for EBS dated on 2020-04-27: Stocks That Hit 52-Week Highs On Monday

Financial news for EBS dated on 2020-04-26: The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight

Financial news for EBS dated on 2020-04-24: Stocks That Hit 52-Week Highs On Friday

Financial news for EBS dated on 2020-04-08: Novavax Identifies COVID-19 Vaccine Candidate, Human Testing To Begin In Mid-May

Financial news for EBS dated on 2020-04-03: The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO

Financial news for EBS dated on 2020-04-02: Emergent BioSolutions Reports Partnership With US Gov't. For Comprehensive Response To Expedite Development Of Plasma-Derived Therapy For Coronavirus

Financial news for EBS dated on 2020-04-01: 10 Biotech Winners And Losers In Q1

Financial news for EBS dated on 2020-04-01: The Daily Biotech Pulse: InflaRx Begins Human Testing For COVID-induced Pneumonia, Chembio, Becton Dickinson Launch Coronavirus Tests

Financial news for EBS dated on 2020-03-31: Emergent BioSolutions Signs Agreement With Novavax To Manufacture NanoFlu

Financial news for EBS dated on 2020-03-18: Vaxart, Emergent Biosolutions Partner On Coronavirus Vaccine Development

Financial news for EBS dated on 2020-03-18: The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates

Financial news for EBS dated on 2020-03-18: Emergent BioSolutions and Vaxart shares are trading higher after the companies announced they have entered into an agreement for the development and manufacturing of the oral Coronavirus vaccine candidate.

Financial news for EBS dated on 2020-03-18: Vaxart Announces It Entered Into An Agreement With Emergent Biosolutions For The Development And Manufacturing Of Oral Coronavirus Vaccine Candidate

Financial news for EBS dated on 2020-03-12: Emergent BioSolutions CEO Talks Coronavirus Vaccine Development

Financial news for EBS dated on 2020-03-12: The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO

Financial news for EBS dated on 2020-03-11: Emergent BioSolutions Reports Initiation Of Development Of Plasma-Derived Product Candidates For Treatment Of Coronavirus

Financial news for EBS dated on 2020-03-10: Teladoc, Ping Identity, Emergent Biosolutions: Portfolio Manager Shares Stock Picks After Monday's Carnage

Financial news for EBS dated on 2020-03-10: Emergent BioSolutions Earlier Signs Development and Manufacturing Agreement With Novavax for Experimental Vaccine Candidate for Coronavirus Disease

Financial news for EBS dated on 2020-03-10: The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index

Financial news for EBS dated on 2020-02-25: Wells Fargo Maintains Overweight on Emergent BioSolutions, Raises Price Target to \$75

Financial news for EBS dated on 2020-02-21: Stocks That Hit 52-Week Highs On Friday

Financial news for EBS dated on 2020-02-20: Emergent BioSolutions Sees FY20 Sales \$1.175B-\$1.275B vs \$1.23B Est.

Financial news for EBS dated on 2020-02-20: Emergent BioSolutions Q4 Adj. EPS \$1.57 Misses \$1.73 Estimate, Sales \$360.4M Beat \$358.7M Estimate

Financial news for EBS dated on 2020-02-20: The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study

Financial news for EBS dated on 2020-02-20: Earnings Scheduled For February 20, 2020

Financial news for EBS dated on 2020-02-16: The Week Ahead In Biotech: Baudax Bio, Merck, Esperion Await FDA Decisions

Financial news for EBS dated on 2020-01-31: Emergent BioSolutions Reports Receives Positive CHMP Opinion For Vaxchora; Sees Near-Term Approval By EMA

Financial news for EBS dated on 2020-01-13: Emergent Biosolutions Receives European Medicine Agency Approval to Pursue its Proposed Development Plan for Chikungunya

Financial news for EBS dated on 2020-01-13: Emergent BioSolutions Narrows FY2019 Sales Guidance from \$1.06B-1.14B to \$1.1B-1.105B vs \$1.11B Est.

Financial news for EBS dated on 2019-11-22: Emergent BioSolutions Highlights Presentation Of Immunogenicity Results From Phase 2 Study Of Investigational Chikungunya VLP Vaccine Candidate

Financial news for EBS dated on 2019-11-06: Emergent BioSolutions Q3 EPS \$1.21 Beats \$0.9 Estimate, Sales \$311.8M Beat \$289.27M Estimate

Financial news for EBS dated on 2019-11-06: The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings

Financial news for EBS dated on 2019-10-10: Emergent BioSolutions Reports Received European Medicines Agency Prime Designation For Chikungunya Virus Virus-Like Particle Vaccine Candidate

Financial news for EBS dated on 2019-09-27: Emergent BioSolutions Reports Received \$6.3M NIH Research Grant To Further Develop AP007 For Treatment for Opioid Use Disorder

Financial news for EBS dated on 2019-09-25: Emergent BioSolutions Wins \$20M To Develop Diazepam Auto-Injector To Treat Nerve Agent-Induced Seizures For US Department Of Defense

Financial news for EBS dated on 2019-09-12: Benzinga's Top Upgrades, Downgrades For September 12, 2019

Financial news for EBS dated on 2019-09-12: Guggenheim Initiates Coverage On Emergent BioSolutions with Buy Rating, Announces \$65 Price Target

Financial news for EBS dated on 2019-09-05: 60 Biggest Movers From Yesterday

Financial news for EBS dated on 2019-09-04: Wells Fargo Upgrades Emergent Biosolutions After Smallpox Vaccine Announcement

Financial news for EBS dated on 2019-09-04: Benzinga's Top Upgrades, Downgrades For September 4, 2019

Financial news for EBS dated on 2019-09-04: Wells Fargo Upgrades Emergent BioSolutions to Outperform, Raises Price Target to \$64

Financial news for EBS dated on 2019-09-04: 66 Biggest Movers From Yesterday

Financial news for EBS dated on 2019-09-03: 44 Stocks Moving In Tuesday's Mid-Day Session

Financial news for EBS dated on 2019-09-03: Mid-Morning Market Update: Markets Open Lower; Conn's Beats Q2 Expectations

Financial news for EBS dated on 2019-09-03: Emergent BioSolutions Awarded 10-Year HHS Contract To Deliver ACAM2000 Smallpox Vaccine To US Strategic National Stockpile

Financial news for EBS dated on 2019-08-01: Emergent BioSolutions Q2 EPS \$(0.18) May Not Compare To \$0.17 Estimate, Sales \$243.2M Beat \$212.06M Estimate

Financial news for EBS dated on 2019-08-01: The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings

Financial news for EBS dated on 2019-07-27: The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Financial news for EBS dated on 2019-07-11: Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.

Financial news for EBS dated on 2019-07-08: Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.

Financial news for EBS dated on 2019-06-07: Many US-traded stocks are trading higher as new economic signals have raised the potential for a Federal Reserve rate cut.

Financial news for EBS dated on 2019-06-04: Emergent BioSolutions Reports FDA Approval Of Change In Storage Conditions, Transfer Of Manufacturing for Cholera Vaccine

Financial news for EBS dated on 2019-06-04: Emergent BioSolutions Announces FDA Approval Af Change In Storage Conditions And Transfer Of Manufacturing For Its Cholera Vaccine

Financial news for EBS dated on 2019-06-03: Shares of several biotechs are trading higher in sympathy with Amgen after the company presented the first clinical data evaluating a KRASG12C inhibitor, AMG 510, at ASCO 2019.

Financial news for EBS dated on 2019-06-03: A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street

Financial news for EBS dated on 2019-06-03: Emergent BioSolutions Wins a \$35M Contract from the US Department of Health and Human Services

Financial news for EBS dated on 2019-05-31: The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering

Financial news for EBS dated on 2019-05-30: The Daily Biotech Pulse: Unity Biotech Licenses Anti-Aging Protein, Strong Results For Mereo's Brittle Bone Disease Drug

Financial news for EBS dated on 2019-05-21: The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular's Glaucoma Trial Fails

Financial news for EBS dated on 2019-05-20: Emergent BioSolutions Reports 5 EU Countries Have Granted Marketing Authorization For Oral Typhoid Vaccine

Financial news for EBS dated on 2019-05-15: Emergent BioSolutions Reports Prepared For Initial Shipments Of AV7909 Anthrax Vaccine Candidate Into Strategic National Stockpile

Financial news for EBS dated on 2019-05-14: The Daily Biotech Pulse: Further Delay in Roche's Spark Acquisition, FDA Nod For Regeneron, Solid Biosciences Sinks On Earnings

Financial news for EBS dated on 2019-05-10: The Daily Biotech Pulse: FibroGen Kidney Disease Trial Disappoints, Medtronic To Buy Titan Spine, Puma's Weak Breast Cancer Drug Sales

Financial news for EBS dated on 2019-05-08: The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split

Financial news for EBS dated on 2019-05-03: Emergent BioSolutions shares are trading lower after the company reported worse-than-expected Q1 EPS and sales results.

Financial news for EBS dated on 2019-05-02: Emergent BioSolutions Q1 Adj. EPS \$(0.13) Misses \$0.09 Estimate, Sales \$190.6M Miss \$201.16M Estimate

Financial news for EBS dated on 2019-05-02: The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data

Financial news for EBS dated on 2019-04-16: Emergent BioSolutions Says Interim Analysis Of Phase 2 Of CHIKV-VLP, A Chikungunya Virus Vaccine Candidate, Neutralized Antibody Response In 98% Of Patients

Financial news for EBS dated on 2019-03-19: Emergent BioSolutions Initiates Phase 3 Clinical Study To Evaluate AV7909 For Post-Exposure Prophylaxis Of Anthrax

Financial news for EBS dated on 2019-03-13: Emergent Biosolutions Shares Rebound From Session Low, Hearing Cantor Fitzgerald Sees News By Purdue Pharma A Nonevent For Co., Will Have No Effect On Narcan

Financial news for EBS dated on 2019-02-28: Emergent Biosciences Wins Us Dept. Of State Contract To Supply Medical Countermeasures For Chemical Warfare Agents, Comprised Of 5-Year Base For Minimum Of \$7M To Maximum \$100M

Financial news for EBS dated on 2019-02-21: Emergent BioSolutions Q4 EPS \$0.75 Beats \$0.62 Estimate, Sales \$270.7M Beat \$270.4M Estimate

Financial news for EBS dated on 2019-01-07: Emergent BioSolutions Sees FY2019 Sales \$1.06B-1.14B vs \$1.02B Est

Financial news for EBS dated on 2019-01-07: Emergent BioSolutions Narrows FY2018 Sales Guidance from \$770.0M-800.0M to \$779.0M-784.0M vs \$778.95M Est

Financial news for EBS dated on 2018-12-28: Emergent BioSolutions Reports Submission To FDA Of Its Application Covering Emergency Use Authorization For NuThrax

Financial news for EBS dated on 2018-12-18: Watching Emergent Biosolutions Shares; Hearing FDA Panel Has Voted 12-11 To Recommend Co-Prescribing Of Naloxone For Patients With Prescribed Opioids

Financial news for EBS dated on 2018-12-17: Emergent BioSolutions Reports Received Health Canada Approval Of BioThrax

Financial news for EBS dated on 2018-12-04: Stocks Which Set New 52-Week High Yesterday, Mon., Dec. 3, 2018

Financial news for EBS dated on 2018-12-04: The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO

Financial news for EBS dated on 2018-11-30: Stocks Which Set New 52-Week High Yesterday, Thurs., Nov. 29, 2018

Financial news for EBS dated on 2018-11-30: The Daily Biotech Pulse: EC Nod For Shire, Mirati Gets FDA Clearance For Cancer Drug Trials, PhaseBio's First Earnings

Financial news for EBS dated on 2018-11-29: Stocks Which Set New 52-Week High Yesterday, Wed., Nov. 28, 2018

Financial news for EBS dated on 2018-11-27: Stocks Which Set New 52-Week High Yesterday, Mon., Nov. 26, 2018

Financial news for EBS dated on 2018-11-27: The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial

Financial news for EBS dated on 2018-11-26: Stocks Which Set New 52-Week High The Prior Trading Session, Fri., Nov. 23, 2018

Financial news for EBS dated on 2018-11-19: Emergent Biosolutions, Valneva Report Phase 1 Results For Vaccine Candidate Against Zika: Met Primary Endpoint For Safety

Financial news for EBS dated on 2018-11-08: Stocks Which Set New 52-Week High Yesterday, Wed., Nov. 7, 2018

Financial news for EBS dated on 2018-11-08: The Daily Biotech Pulse: Nantkwest Reports Positive Cancer Vaccine Trial Results, Sarepta Offering

Financial news for EBS dated on 2018-11-02: 10 Biggest Price Target Changes For Friday

Financial news for EBS dated on 2018-11-02: Goldman Sachs Upgrades Emergent BioSolutions to Buy, Raises Price Target to \$75

Financial news for EBS dated on 2018-11-01: Emergent Biosolutions Raises FY18 Sales Guidance From \$715M-\$755M To \$770M-\$800M, Adj. Net Income \$110M-\$125M To \$105M-\$115M

Financial news for EBS dated on 2018-11-01: Emergent Biosolutions, Inc. Q3 EPS \$0.55 Misses \$0.58 Estimate, Sales \$173.653M Miss \$184.1M Estimate

Financial news for EBS dated on 2018-11-01: The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal

Financial news for EBS dated on 2018-10-27: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs

Financial news for EBS dated on 2018-10-25: UPDATE: Emergent Notes Co.'s Adapt Units, Opiant Pharma, On Oct. 25, 2018, Filed Complaint For Patent Infringement Against Perrigo In US Related To Perrigo's ANDA Filing With FDA

Financial news for EBS dated on 2018-10-25: Emergent BioSolutions 8-K Shows Adapt Pharma Received Notice From Perrigo UK FINCO That Perrigo Filed Abbreviated New Drug Application Seeking Approval To Market Generic Version Of NARCAN Nasal Spray

Financial news for EBS dated on 2018-10-05: The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker

Financial news for EBS dated on 2018-09-21: The Daily Biotech Pulse: Exelixis Liver Cancer Drug On Track For European Approval, Medtronic Goes Shopping, Opiant Snags BARDA Funding

Financial news for EBS dated on 2018-09-21: Stocks Which Set New 52-Week High Yesterday, September 20th

Financial news for EBS dated on 2018-09-20: Stocks Which Set New 52-Week High Yesterday, September 19th

Financial news for EBS dated on 2018-09-20: The Daily Biotech Pulse: Adverum Snags Fast Track Designation, Crispr To Offer Shares, Elanco Animal Health To Debut

Financial news for EBS dated on 2018-09-19: The Daily Biotech Pulse: Johnson & Johnson's Generic Unit Files NDA For Urinary Tract Cancer Drug, G1 Therapeutics Prices Offering

Financial news for EBS dated on 2018-09-18: Stocks Which Set New 52-Week High Yesterday, September 17th

Financial news for EBS dated on 2018-09-18: The Daily Biotech Pulse: Morphosys Expands Collaboration, Osiris Announces Product Launch, Argenx To Offer Shares

Financial news for EBS dated on 2018-09-17: Stocks Which Set New 52-Week High Friday, September 14th

Financial news for EBS dated on 2018-08-31: Stocks Which Set New 52-Week High Yesterday, August 30th

Financial news for EBS dated on 2018-08-31: The Daily Biotech Pulse: FDA Blessings for Merck's HIV Drug Combo, Veracyte's Test Gets Medicare Coverage

Financial news for EBS dated on 2018-08-30: Stocks Which Set New 52-Week High Yesterday, August 29th

Financial news for EBS dated on 2018-08-30: The Daily Biotech Pulse: Verastem Gets New CFO, Mesoblast Earnings, Vertex's Precision Medicine Collaboration

Financial news for EBS dated on 2018-08-29: Stocks Which Set New 52-Week High Yesterday, August 28th

Financial news for EBS dated on 2018-08-29: Opiant Pharmaceuticals Shares Up 81% Premarket Following Tuesday's After Hours News Its Commercial Partner, Adapt Pharma, To Be Acquired By Emergent Biosolutions For \$735M

Financial news for EBS dated on 2018-08-29: The Daily Biotech Pulse: Assertio Settles With Purdue, Emergent Biosolutions In M&A Mix, Novartis Eye Care Unit Recalls Stent

Financial news for EBS dated on 2018-08-28: UPDATE: Emergent To Acquire Adapt Pharma For \$735M Total Consideration Consisting Of Upfront Payment Of \$635M And Up To \$100M In Cash For Potential Sales-Based Milestones; Upfront Payment Includes \$575M In Cash And \$60M Emergent Common Stock

Financial news for EBS dated on 2018-08-28: UPDATE: Emergent Biosolutions Expects To Generate Rev. Of \$200-\$220M And For Acquisition Of Adapt Pharma To Be Accretive To Adj. Net Income And EBITDA In 2019

Financial news for EBS dated on 2018-08-28: Emergent Biosolutions Acquires Adapt Pharma And NARCAN Nasal Spray For Total Consideration Of \$735M

Financial news for EBS dated on 2018-08-28: The Daily Biotech Pulse: Regulatory Roadblock For Akcea-Ionis, Affimed's Alliance, FDA Nod For Tetrphase's Antibiotic

Financial news for EBS dated on 2018-08-27: Stocks Which Set New 52-Week High Friday, August 24th

Financial news for EBS dated on 2018-08-24: Stocks Which Set New 52-Week High Yesterday, August 23rd

Financial news for EBS dated on 2018-08-24: The Daily Biotech Pulse: Immunomedics' Bottom-Line Miss; Kala, Regeneron Await FDA Verdict

Financial news for EBS dated on 2018-08-23: Stocks Which Set New 52-Week High Yesterday, August 22nd

Financial news for EBS dated on 2018-08-23: The Daily Biotech Pulse: Novartis Breast Cancer Trial Meets Endpoint, Medpace's Offering, Dexcom Buys TypeZero

Financial news for EBS dated on 2018-08-22: Stocks Which Set New 52-Week High Yesterday, August 21st

Financial news for EBS dated on 2018-08-22: The Daily Biotech Pulse: FDA Snub For Allergan, Myriad's Q4 Beat, Mallinckrodt's Stannsoporfin

Financial news for EBS dated on 2018-08-21: Stocks Which Set New 52-Week High Tues., Aug. 21, 2018

Financial news for EBS dated on 2018-08-16: Emergent BioSolutions Announces Collaboration With Profectus BioSciences; The Companies Will Receive Up To \$36M Contract From CEPI To Develop Lassa Virus Vaccine

Financial news for EBS dated on 2018-08-15: Shares Of Emergent Biodefense Volatile As Traders Circulate An Earlier CDC FedBizOpps Document Showing The Purchase Of 9M Doses Of ACAM2000 Smallpox Vaccine

Financial news for EBS dated on 2018-08-09: Emergent BioSolutions Reports Purchase Of PaxVax For \$270M In Cash

Financial news for EBS dated on 2018-08-06: Stocks Which Set New 52-Week Highs Friday, August 3rd

Financial news for EBS dated on 2018-08-03: Emergent Biosolutions Filing Shows Registration For Mixed Securities Shelf Offering, No Terms Disclosed

Financial news for EBS dated on 2018-08-02: Emergent BioSolutions Sees Q3 Sales \$165M-\$190M vs \$201.89M Est.

Financial news for EBS dated on 2018-08-02: Emergent BioSolutions Q2 Adj. EPS \$1.07 Beats \$0.88 Estimate, Sales \$220.2M Beat \$208.57M Estimate

Financial news for EBS dated on 2018-08-02: The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter

Financial news for EBS dated on 2018-07-31: Emergent BioSolutions Reports Initiation Of Phase 1 Clinical Study To Evaluate Safety, Pharmacokinetics Of ZIKV-IG

Financial news for EBS dated on 2018-07-28: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Financial news for EBS dated on 2018-06-15: Benzinga's Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid Addiction Drug

Financial news for EBS dated on 2018-06-13: Argus: Anthrax Vaccine Maker Emergent BioSolutions Poised For Earnings Growth

Financial news for EBS dated on 2018-06-13: Benzinga's Top Upgrades, Downgrades For June 13, 2018

Financial news for EBS dated on 2018-06-13: Argus Initiates Coverage On Emergent BioSolutions with Buy Rating, Announces \$62 Price Target

Financial news for EBS dated on 2018-06-11: Cantor Fitzgerald Initiates Coverage On 8 Pharma/Biotech Stocks After Hours: 7 With Overweight, 1 With Neutral Rating

Financial news for EBS dated on 2018-06-07: Emergent BioSolutions Announces \$50 Million Expansion Of Baltimore Fill/Finish Facility To Support Growth Of Contract Development And Manufacturing Capabilities

Financial news for EBS dated on 2018-05-24: Emergent BioSolutions Reports \$25M Collaboration With Profectus Biosciences, The Coalition For Epidemic Preparedness Innovations To Advance The Development, Manufacture Of Vaccine Against Nipah Virus

Financial news for EBS dated on 2018-05-03: Emergent BioSolutions Sees FY2018 Sales \$715.0M-755.0M vs \$731.40M Est

Financial news for EBS dated on 2018-05-03: Emergent BioSolutions Q1 EPS \$(0.03) Misses \$0.20 Estimate, Sales \$117.8M Miss \$140.42M Estimate

Financial news for EBS dated on 2018-04-25: Emergent Biosolutions' Stock Run Can't Continue Forever, Wells Fargo Says In Downgrade

Financial news for EBS dated on 2018-04-25: Benzinga's Top Upgrades, Downgrades For April 25, 2018

Financial news for EBS dated on 2018-04-25: Wells Fargo Downgrades Emergent BioSolutions to Market Perform

Financial news for EBS dated on 2018-04-12: Emergent BioSolutions Reports Successful Completion Of Mutual Recognition Procedure For Market Authorization Of BioThrax In Europe

Financial news for EBS dated on 2018-03-22: Emergent BioSolutions Announces \$50M Buyback

Financial news for EBS dated on 2018-02-28: Emergent BioSolutions Reports Winning Of 1-Year CDC Contract For Vaccinia Immune Globulin Program, Valued At \$26M

Financial news for EBS dated on 2018-02-22: UPDATE: Emergent BioSolutions Sees FY2020 Sales \$1B, Profit Margin 14%+

Financial news for EBS dated on 2018-02-22: Emergent BioSolutions Sees Q1 Sales Outlook Cut From \$145M-\$160M to \$125M-\$150M; FY18 Adj. Net Income \$110M-\$125M, Sales \$715M-\$755M vs \$706.01M Est.

Financial news for EBS dated on 2018-02-22: Emergent BioSolutions Reports Q4 Adj. EPS \$0.67 vs \$0.70 Est., Sales \$193.8M vs \$188.95M Est.

Financial news for EBS dated on 2018-02-19: The Week Ahead In Biotech: Earnings, PDUFA Dates And More

Financial news for EBS dated on 2018-01-24: Goldman Sachs Initiates Coverage On Emergent BioSolutions with Neutral Rating, Announces \$55.00 Price Target

Financial news for EBS dated on 2018-01-08: Emergent BioSolutions Narrows, Raises FY17 Sales Guidance From \$540M-\$560M To \$555-\$560M, Adj. Net Income From \$85M-\$95M To

\$92-\$96M

Financial news for EBS dated on 2018-01-04: Emergent BioSolutions Begins Phase 2 Clinical Study to Evaluate FLU-IGIV, Phase 2 Study To Enroll ~75 Patients

Financial news for EBS dated on 2017-12-12: Emergent BioSolutions Wins a Contract from the Canadian Department of National Defense for \$8M to Supply Anthrasil

Financial news for EBS dated on 2017-12-04: 4 Biotech Stocks To Better Your Financial Health This Winter

Financial news for EBS dated on 2017-11-20: Emergent BioSolutions Announces FDA Approval to Manufacture ACAM2000 at Canton, Massachusetts Facility

Financial news for EBS dated on 2017-11-02: Emergent BioSolutions Increases FY17 Sales From \$500-\$530M To \$540-\$560M

Financial news for EBS dated on 2017-11-02: Emergent BioSolutions Reports Q3 EPS \$0.68 vs \$0.41 Est., Sales \$149.43M vs \$124.55M Est.

Financial news for EBS dated on 2017-10-04: Emergent BioSolutions Wins \$25M Contract with the US Department of State

Financial news for EBS dated on 2017-09-25: Emergent BioSolutions Wins \$171M Department of Defense Contract Related to Chemical Threat

Financial news for EBS dated on 2017-09-18: Emergent Biosolutions Awarded \$63M BARDA Contract

Financial news for EBS dated on 2017-08-03: Emergent BioSolutions Reports Q2 Adj. Net Income \$6.6M, Sales \$100.8M vs \$111.6M Est.

Financial news for EBS dated on 2017-07-31: Emergent BioSolutions Reports Winning Of \$23M Contract To Develop Novel Multi-Drug Auto-Injector For US Dept. Of Defense

Financial news for EBS dated on 2017-07-26: Emergent BioSolutions Reports Securing Of Exclusive Global Rights To Valneva's Zika Vaccine Technology

Financial news for EBS dated on 2017-07-19: UPDATE: Emergent BioSolutions Deal For Raxibacumab Will Include \$76M Upfront Cash Payment, \$20M In Product Sale, Manufacturing-Related Milestone Payments

Financial news for EBS dated on 2017-07-19: Emergent BioSolutions Reports Will Buy Raxibacumab From GSK For ~\$130M

Financial news for EBS dated on 2017-07-14: Emergent BioSolutions Reports Purchase Of ACAM2000 Unit From Sanofi For ~\$125M In Cash

Financial news for EBS dated on 2017-05-04: Emergent BioSolutions Q2 Sales \$100-\$115M vs \$122M Est.

Financial news for EBS dated on 2017-05-04: Emergent BioSolutions Reports Q1 EPS \$0.23 vs \$0.30 Est., Sales \$116.85M vs \$116M Est

Financial news for EBS dated on 2017-04-06: Anthrax And Government Contracts: PharmAthene And Altimune Ahead Of Merger

Financial news for EBS dated on 2017-03-17: Emergent BioSolutions Reports Winning of \$100M BARDA Contract for BioThrax Deliveries to Strategic National Stockpile

Financial news for EBS dated on 2017-02-23: Emergent BioSolutions Reports Q4 Adj. EPS \$0.74 vs \$0.48 Est., Sales \$151.663M vs \$120.45M Est.

Financial news for EBS dated on 2017-01-13: Aptevio Therapeutics Receives \$20M Payment From Emergent Biosolutions

Financial news for EBS dated on 2017-01-09: Emergent BioSolutions Reports Prelim FY16 Rev. \$480-\$485M, EBITDA \$131-\$135M; Sees FY17 Rev. \$500-\$530M

Financial news for EBS dated on 2017-01-03: Soligenix, Emergent Biosolutions Continue Development Agreement With NIAID Contract Funding Up To \$24.7M

Financial news for EBS dated on 2016-12-12: Emergent BioSolutions Receives Health Canada Approval for Botulism Antitoxin

Financial news for EBS dated on 2016-12-09: Mid-Afternoon Market Update: Restoration Hardware Tumbles On Weak Guidance; Stillwater Mining Shares Spike Higher

Financial news for EBS dated on 2016-12-09: Mid-Morning Market Update: Markets Open

Higher; Finisar Beats Q2 Estimates

Financial news for EBS dated on 2016-12-08: UPDATE: Emergent Sees FY16 Sales on Continuing Operations Basis \$465M-\$485M vs \$459M Est., EBITDA \$120M-\$130M

Financial news for EBS dated on 2016-12-08: Emergent Biosolutions Reports Will Support HHS Anthrax Preparedness Strategy with Up to \$1B in BioThrax Deliveries to Strategic National Stockpile

Financial news for EBS dated on 2016-11-07: Emergent BioSolutions Reports Q3 EPS \$0.58 vs. Prior Year Quarter \$0.93, Rev. \$142.9M

Financial news for EBS dated on 2016-09-30: Emergent Biosolutions Shares Up 13% on Heavy Volume; Co. Earlier Offered Update on Status of BioThrax Procurement contract, Discussions with CDC

Financial news for EBS dated on 2016-08-15: Emergent BioSolutions Receives FDA Approval for Large-Scale Manufacturing of BioThrax in Building 55

Financial news for EBS dated on 2016-08-04: Emergent Biosolutions Reports Q2 Adj. EPS \$(0.18) vs \$(0.17) Est., Sales \$101.5M vs \$111.2M Est.

Financial news for EBS dated on 2016-07-20: Emergent BioSolutions Spinoff Aptevo To Begin Trading Today Under Ticker APVO

Financial news for EBS dated on 2016-07-15: Emergent BioSolutions To Implement \$50 Million Share Buyback Program

Financial news for EBS dated on 2016-07-15: Emergent BioSolutions Announces \$50M Buyback

Financial news for EBS dated on 2016-06-27: Emergent BioSolutions Receives BARDA Order Up to \$21.9 Million to Develop and Manufacture a Zika Vaccine

Financial news for EBS dated on 2016-06-22: JP Morgan On Emergent BioSolutions: HHS Update Driving Quicker-Than-Anticipated Transition To Next-Gen Vaccine, Negative Outlooks On Estimates For BioThrax In 2017

Financial news for EBS dated on 2016-06-22: 10 Biggest Mid-Day Losers For Wednesday

Financial news for EBS dated on 2016-06-22: Hearing Wells Fargo Defending Emergent Biosolutions Inc

Financial news for EBS dated on 2016-06-17: Emergent BioSolutions Says FDA Accepts Its sBLA For Large-Scale Manufacturing Of BioThrax In Building 55

Financial news for EBS dated on 2016-06-17: FDA Accepts Emergent BioSolutions' Supplemental Biologics License Application for Large-Scale Manufacturing of BioThrax in Building 55

Financial news for EBS dated on 2016-06-15: Emergent Biosolutions Reports FDA Orphan Drug Designation for BioThrax for Post-Exposure Prophylaxis of Anthrax Disease

Financial news for EBS dated on 2016-05-05: Emergent BioSolutions Reports Q1 EPS \$0.16 vs. Est. \$(0.07), Rev. \$111M vs. Est. \$101.8M

Financial news for EBS dated on 2016-04-18: Emergent Biosolutions Reveals sBLA Submission To FDA To Make BioThrax In Building 55

Financial news for EBS dated on 2016-04-18: Emergent BioSolutions Submits sBLA for FDA Approval of Large-Scale Manufacturing of BioThrax in Building 55

Financial news for EBS dated on 2016-04-15: Chardan Capital Initiates Coverage on Emergent BioSolutions at Buy, Announces \$47.00 PT

Financial news for EBS dated on 2016-03-28: Singular Research Initiates Coverage on Emergent BioSolutions at Buy, Announces \$44.00 PT

Financial news for EBS dated on 2016-02-25: Emergent BioSolutions Sees Q1 Rev. \$105-\$120M vs. Est. \$94M, FY16 Rev. \$600-\$630M vs. Est. \$582M

Financial news for EBS dated on 2016-02-25: Emergent BioSolutions Reports Q4 EPS \$0.78 vs. Est. \$0.70, Rev. \$168.1M vs. Est. \$168M

Financial news for EBS dated on 2016-02-19: Wells Fargo Initiates Coverage on Emergent BioSolutions at Outperform

Financial news for EBS dated on 2016-02-17: Emergent BioSolutions Reports Co.'s Emergard Platform for Nerve Agent Antidote Delivery Has Been Chosen by Us Dept. of

Defense and Battelle for Testing, Development

Financial news for EBS dated on 2016-01-13: Ligand Reports OmniAb Platform Licensing Deal with Emergent BioSolutions

Financial news for EBS dated on 2016-01-11: Emergent Biosolutions Releases Preliminary 2015 Results, 2016 Outlook And Strategic Growth Plan Through 2020

Financial news for EBS dated on 2016-01-11: Emergent BioSolutions Sees FY2016 Sales \$600.0M-630.0M vs \$544.32M Est

Financial news for EBS dated on 2016-01-11: Emergent BioSolutions Sees Q1 Sales \$105.0M-120.0M vs \$83.0M Est

Financial news for EBS dated on 2016-01-11: Emergent BioSolutions Sees FY2015 EPS \$1.54-1.63 vs \$1.51 Est; Sees Sales \$520.0M-525.0M vs \$524.80M Est

Financial news for EBS dated on 2016-01-10: Emergent BioSolutions Announces Favorable IRS Private Letter Ruling Regarding Biosciences Business Spin-Off

Financial news for EBS dated on 2015-12-22: Emergent BioSolutions Announces Composition of Board of Directors of New Spin-Off Company Aptevo Therapeutics

Financial news for EBS dated on 2015-11-24: FDA Approves Emergent BioSolutions' BioThrax for Post-Exposure Prophylaxis

Financial news for EBS dated on 2015-11-23: FDA Approves New Indication for BioThrax -DJ

Financial news for EBS dated on 2015-11-05: Emergent Biosolutions Q3 EPS \$0.79 Vs Est \$0.55, Sales \$164.9M Vs Est \$151.42M

Financial news for EBS dated on 2015-10-19: Cowen: In Biotech Earnings We Trust

Financial news for EBS dated on 2015-08-13: Emergent BioSolutions Receives \$44M CDC Contract to Further Advance Vaccinia Immune Globulin Intravenous Program

Financial news for EBS dated on 2015-08-06: Emergent Biosolutions Reports Q2 EPS \$0.36 vs. Est. \$0.18, Rev. \$126.1M vs. Est. \$114.25M

Financial news for EBS dated on 2015-08-06: Emergent BioSolutions to Spin-Off of Biosciences Business Into Separate Publicly-Traded Company in Tax-Free Transaction

Financial news for EBS dated on 2015-07-20: UPDATE: Emergent Biosolutions Announces \$19.7M Contract

Financial news for EBS dated on 2015-07-20: Emergent Biosolutions Announces \$19.7M Contract

Financial news for EBS dated on 2015-07-20: Emergent BioSolutions Awarded \$19.7 Million BARDA Contract to Develop, Manufacture Ebola Monoclonal Antibodies

Financial news for EBS dated on 2015-06-09: Pentagon Says Britain Added to List of Countries With Labs That Received Live Anthrax from US Military -Reuters

Financial news for EBS dated on 2015-05-29: US Military Discovers Another Shipment of Live Anthrax from 2008 Batch Sent to Australia -Reuters

Financial news for EBS dated on 2015-05-28: US Stock Futures Down Ahead Of Jobless Claims

Financial news for EBS dated on 2015-05-28: ProMetic Life Science to Acquire Emergent Biosolutions' Plasma Collection Center in Winnipeg, Canada

Financial news for EBS dated on 2015-05-27: Pentagon Confirms Inadvertent Transfer of Samples Containing Live Anthrax, Says No Risk to Public -Reuters

Financial news for EBS dated on 2015-05-22: S-3ASR Emergent Biosolutions Files Automatic Mixed Shelf Registration

Financial news for EBS dated on 2015-05-19: Emergent BioSolutions Signs Long-Term Manufacturing Agreement With Prometic Life Sciences

Financial news for EBS dated on 2015-05-19: Emergent BioSolutions, Prometic Life Sciences Agree To Long-Term Manufacturing Agreement

Financial news for EBS dated on 2015-05-07: Emergent BioSolutions Reports Q1 Loss \$0.57 Vs Est Loss \$0.44, Sales \$63.6M Vs Est \$56.50M

Financial news for EBS dated on 2015-04-30: Emergent BioSolutions Announces FDA Approval of IXINITY for Hemophilia B

Financial news for EBS dated on 2015-04-23: Evolva Completes Transfer of EV-035 to Emergent BioSolutions; Triggers \$4M Payment

Financial news for EBS dated on 2015-03-25: Emergent Biosolutions Announces FDA Approval of Anthrasil

Financial news for EBS dated on 2015-03-24: Emergent BioSolutions Awarded \$31 Million Contract for Advanced Development of NuThrax, a Next Generation Anthrax Vaccine

Financial news for EBS dated on 2015-03-16: Emergent BioSolutions Signs Agreements With Oxford University, GlaxoSmithKline, and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate

Financial news for EBS dated on 2015-03-09: Emergent BioSolutions and MorphoSys Initiate Phase 1 Clinical Study to Evaluate the Novel Oncology Immunotherapeutic MOR209/ES414 for Prostate Cancer

Financial news for EBS dated on 2015-03-09: MorphoSys Emergent BioSolutions, Initiate Phase 1 Clinical Study to Evaluate MOR209/ES414 for Prostate Cancer

Financial news for EBS dated on 2015-03-06: Morning Market Losers

Financial news for EBS dated on 2015-03-05: After-Hours Movers Led By Calithera Biosciences, Violin Memory & PowerSecure

Financial news for EBS dated on 2015-03-05: Emergent Biosolutions Reports Q4 Adj. EPS \$0.75 vs. \$0.69, Rev. \$148M vs. Est. \$147M; Stock Trending Down 0.81% To \$29.24

Financial news for EBS dated on 2015-01-11: Emergent BioSolutions Sees Q1 Sales \$90.0M-105.0M vs \$147.75M Est

Financial news for EBS dated on 2015-01-11: Emergent BioSolutions Sees FY2015 Sales \$510.0M-540.0M vs \$486.25M Est

Financial news for EBS dated on 2015-01-11: Emergent BioSolutions Sees FY2014 Sales \$445.0M-450.0M vs \$449.87M Est

Financial news for EBS dated on 2014-11-10: Emergent Reports Submission of FDA Application for Post-Exposure Prophylaxis, Looking for Expanded Biothrax Label

Financial news for EBS dated on 2014-09-08: Emergent BioSolutions Awarded \$29M 5-Year Contract To Develop A Dry Formulation Of NuThrax, A Next Generation Anthrax Vaccine

Financial news for EBS dated on 2014-08-19: MorphoSys And Emergent BioSolutions Sign License Agreement to Co-Develop And Commercialize Prostate Cancer Drug Candidate ES414

Financial news for EBS dated on 2014-08-07: Emergent Biosolutions, Inc. Reports Q2 EPS of \$0.13 Which May Not Compare \$0.32 Est; Revenue of \$110.30M Which May Not Compare \$109.25M Est

Financial news for EBS dated on 2014-08-07: Emergent BioSolutions Applies For to FDA for License for Anthra Immune Globulin Intravenous

Financial news for EBS dated on 2014-06-20: UPDATE: CDC Reports Has Identified 86 Potential Exposures to Live Anthrax Bacteria

Financial news for EBS dated on 2014-06-19: Reuters Reports CDC Says As Many As 75 Of Its Scientists May Have Been Accidentally Exposed To Live Anthrax

Financial news for EBS dated on 2014-05-15: Summer Street Initiates Coverage on Emergent Biosolutions, Inc. at Buy, Announces \$35.00 PT

Financial news for EBS dated on 2014-05-08: Emergent Biosolutions, Inc. Sees FY2014 Sales \$415.0M-445.0M vs \$439.20M Est

Financial news for EBS dated on 2014-05-08: Emergent Biosolutions, Inc. Sees Q2 Sales \$95.0M-110.0M vs \$119.55M Est

Financial news for EBS dated on 2014-05-08: Emergent Biosolutions, Inc. Reports Q1 EPS of \$(0.55) Which May Not Compare \$(0.14) Est; Revenue of \$53.90M Which May Not Compare \$57.30M Est

Financial news for EBS dated on 2014-04-21: US Stock Futures Up Ahead Of Earnings

Financial news for EBS dated on 2014-04-21: Emergent BioSolutions Receives FDA Orphan

Drug Designation for BioThrax for Post-Exposure Prophylaxis of Anthrax Disease

Financial news for EBS dated on 2014-04-16: Emergent BioSolutions Successfully Closes Pivotal Clinical Study Support Expanded Indication for BioThrax

Financial news for EBS dated on 2014-03-06: Emergent Biosolutions, Inc. Sees Q1 Sales \$45.0M-55.0M

Financial news for EBS dated on 2014-03-06: Emergent Biosolutions, Inc. Reports Q1 EPS of \$0.41 vs \$0.36 Est; Revenue of \$98.10M vs \$93.83M Est

Financial news for EBS dated on 2014-02-21: Emergent BioSolutions Completes Acquisition Of Cangene

Financial news for EBS dated on 2014-01-29: Emergent BioSolutions Announces Completion of \$250M Convertible Senior Notes Offering

Financial news for EBS dated on 2014-01-27: Emergent BioSolutions Announces \$35M Option Exercised by Initial Purchasers of Company's Convertible Senior Notes

Financial news for EBS dated on 2013-12-10: Emergent BioSolutions Announces Positive Phase 1b Otlertuzumab Results in Combination with Rituximab in People with CLL

Financial news for EBS dated on 2013-12-09: Emergent BioSolutions Presents Positive Interim Phase 2 Data Evaluating Otlertuzumab in Combination with Bendamustine in People with Relapsed Chronic Lymphocytic Leukemia

Financial news for EBS dated on 2013-11-07: Emergent Biosolutions, Inc. Reports Q3 EPS of \$0.36 vs \$0.21 Est; Revenue of \$89.10M vs \$79.13M Est

Financial news for EBS dated on 2013-08-05: Emergent Biosolutions, Inc. Sees Q3 Sales \$70.0M-80.0M vs \$81.14M Est

Financial news for EBS dated on 2013-08-05: Emergent Biosolutions, Inc. Reports Q2 EPS of \$0.29 vs \$0.21 Est

Financial news for EBS dated on 2013-08-02: Emergent Biosolutions Close Purchase of Healthcare Protective Products Unit from Bracco

Financial news for EBS dated on 2013-07-10: Emergent BioSolutions Advances Program Supporting Licensure of a Post-Exposure Prophylaxis Indication for BioThrax

Financial news for EBS dated on 2013-07-01: Emergent BioSolutions Receives Paul-Ehrlich-Institut Approval to Market BioThrax in Germany

Financial news for EBS dated on 2013-05-02: Emergent Biosolutions, Inc. Reports Q1 EPS of \$(0.22) vs \$(0.14) Est; Revenue of \$43.10M vs \$46.17M Est

Financial news for EBS dated on 2013-04-17: Emergent Biosolutions Moves Higher on Speculation Letter Sent to President Believed to Contain Anthrax, Other Reports Say it's Ricin

Financial news for EBS dated on 2013-04-10: Janney Capital Initiates Coverage on Emergent Biosolutions, Inc. at Buy, Announces \$20.00 PT

Financial news for EBS dated on 2013-04-05: A Peek Into The Market Before The Trading Starts

Financial news for EBS dated on 2013-04-05: Emergent BioSolutions to Expand Front Line CLL Clinical Trial of TRU-016 and Rituximab

Financial news for EBS dated on 2013-03-07: Emergent Biosolutions, Inc. Sees FY2013 Sales \$290.0M-310.0M vs \$300.10M Est

Financial news for EBS dated on 2013-03-07: Emergent Biosolutions, Inc. Sees Q1 Sales \$40.0M-50.0M vs \$59.90M Est

Financial news for EBS dated on 2013-03-07: Emergent Biosolutions, Inc. Reports Q4 EPS of \$0.45, Inline; Revenue of \$94.60M

Financial news for EBS dated on 2013-02-04: Emergent BioSolutions Announces Data from Phase IIb Trial for MVA85A Published in The Lancet

Financial news for EBS dated on 2013-01-17: Emergent BioSolutions Begins Phase 2 Clinical Trial for Anthrax Vaccine NuThrax

Financial news for EBS dated on 2013-01-07: Emergent Biosolutions Looking for FY12 Net Income \$21-24M (Including \$9.6M Charge), Sales \$280-284M; Sees FY13 Adj. Net Income \$20-30M, Sales \$290-310M

Financial news for EBS dated on 2013-01-02: Emergent Receives Orphan Medicinal Product Designation from European Commission for TRU-016 for CLL

Financial news for EBS dated on 2012-12-28: Emergent Biosolutions Secures Exclusive US Commercial Rights to NextGen Pandemic Influenza Vaccine Candidate

Financial news for EBS dated on 2012-12-07: Top 4 NYSE Stocks In The Biotechnology Industry With The Highest ROA

Financial news for EBS dated on 2012-11-19: Emergent BioSolutions Names Robert G. Kramer CFO

Financial news for EBS dated on 2012-11-01: Emergent Biosolutions Reports Q3 EPS \$0.18 vs \$0.14 Est; Revenues \$66.6M vs \$68.49M Est

Financial news for EBS dated on 2012-10-31: Emergent BioSolutions Initiates Phase 1b Study of TRU-016 in Combination with Rituximab

Financial news for EBS dated on 2012-10-24: Top 4 NYSE Stocks In The Biotechnology Industry With The Highest Revenue Estimates

Financial news for EBS dated on 2012-08-02: Emergent Biosolutions Reports Q2 EPS \$0.21 vs \$0.23 Est; Revenues \$70.4M vs \$76.82M Est

Financial news for EBS dated on 2012-06-11: UPDATE: Piper Jaffray Initiates Emergent BioSolutions with Overweight, \$21 PT on Post-BioThrax Potential

Financial news for EBS dated on 2012-06-11: Piper Jaffray Initiates Emergent BioSolutions at Overweight, \$21 PT

Financial news for EBS dated on 2012-05-21: Emergent BioSolutions Announces Stock Repurchase Program of up to \$35M

Financial news for EBS dated on 2012-05-03: Emergent Biosolutions Reports Q1 EPS \$-0.02 May Not Compare to \$-0.15 Est; Revenues \$50.3M vs \$47.32M Est

Financial news for EBS dated on 2012-04-18: European morning wrap: Rule, Britannia!, sterling king of the heap

Financial news for EBS dated on 2012-03-28: European morning wrap: Can't beat a bit of consolidation, is what I say

Financial news for EBS dated on 2012-03-27: European morning wrap: Market in consolidative mood this morning

Financial news for EBS dated on 2012-03-08: Emergent Biosolutions Reports Q4 EPS \$0.78 vs \$0.72 Est; Revenues \$107.90M vs \$109.32M Est

Financial news for EBS dated on 2012-03-08: European morning wrap: Yipeeeeeeee, risk on!!!

Financial news for EBS dated on 2012-03-05: European morning wrap: Helter skelter....NOT. Is it Monday?

Financial news for EBS dated on 2012-01-29: Weekly Traders Homework: Frustrated Bears

Financial news for EBS dated on 2012-01-17: Emergent BioSolutions Subsidiary Announces Contract Modification

Financial news for EBS dated on 2012-01-09: Financial Breakfast: Morning News Summary for January 9, 2012

Financial news for EBS dated on 2012-01-09: UPDATE: Emergent BioSolutions Expects 2012 Revs \$280-\$300M vs \$309M Est

Financial news for EBS dated on 2012-01-09: Emergent BioSolutions Expects 2012 Revs \$280-\$300M vs \$309M Est

Financial news for EBS dated on 2011-12-28: A Peek Into The Market Before The Trading Starts

Financial news for EBS dated on 2011-12-28: Emergent Announces Plans for TRU-016 Program Following Termination of Collaboration with Abbott

Financial news for EBS dated on 2011-12-28: Emergent Initiates Phase 2 Study of TRU-016 in Combination with Bendamustine in Patients with Relapsed Chronic Lymphocytic Leukemia

Financial news for EBS dated on 2011-12-21: Emergent BioSolutions Announces Fuad El-Hibri to Retire as CEO

Financial news for EBS dated on 2011-12-12: European morning wrap: Risk off, innit bro

Financial news for EBS dated on 2011-12-01: Emergent BioSolutions Receives Orphan Drug Designation for Its TRU-016 Protein Therapeutic for the Treatment of Chronic Lymphocytic Leukemia

Financial news for EBS dated on 2011-11-29: WABCO Marks Another Industry First for Advanced Safety Technology in China as Part of Contract With Yutong,

Financial news for EBS dated on 2011-11-17: Emergent BioSolutions Initiates Pivotal Clinical Trial Evaluating a Three-Dose BioThrax Regimen for Post-Exposure Prophylaxis

Financial news for EBS dated on 2011-11-03: Emergent BioSolutions Reports Q3 EPS \$0.04 vs \$0.10 Est; Revenues \$58.80M vs \$63.59M Est

Financial news for EBS dated on 2011-10-24: Top 4 NYSE Stocks In The Biotechnology Industry With The Highest ROE

Financial news for EBS dated on 2011-10-04: UPDATE: Wedbush Lowers PT on EBS to \$31

Financial news for EBS dated on 2011-10-04: Wedbush Lowers PT on Emergent BioSolutions to \$31

Financial news for EBS dated on 2011-10-03: Emergent BioSolutions Receives Award to Supply 44.75 Million Doses of BioThrax to U.S. Government over Five Years

Financial news for EBS dated on 2011-09-27: Progress Software Reports Positive Quarter, Poor Guidance

Financial news for EBS dated on 2011-09-05: European Morning Wrap: FX Market Labours on Labor Day

Financial news for EBS dated on 2011-08-26: Results of Emergent BioSolutions Phase 1a Study on Adjuvanted BioThrax Anthrax Vaccine Published in the Journal Vaccine

Financial news for EBS dated on 2011-08-17: Emergent Announces Initiation of a Phase 1b/2 Study of TRU-016 in Combination with Rituximab and Bendamustine in Subjects with Relapsed - Indolent Lymphoma

Financial news for EBS dated on 2011-08-04: Emergent BioSolutions Reports Q2 EPS \$0.39 vs \$0.34 Est; Revenues \$88.1M vs \$84.20M Est

Financial news for EBS dated on 2011-06-28: Progress Software Roll Over in the After-Hours

Financial news for EBS dated on 2011-06-09: Emergent BioSolutions' Investigational Anthrax Vaccine, NuThrax, Granted Fast Track Designation

Financial news for EBS dated on 2011-06-06: A Peek Into The Market Before The Trading Starts

Financial news for EBS dated on 2011-06-06: Emergent BioSolutions Acquires Late-Stage Monoclonal Antibody Cancer Therapy from TenX BioPharma

Financial news for EBS dated on 2011-05-27: UPDATE: J.P. Morgan Raises PT on Emergent BioSolutions to \$35

Financial news for EBS dated on 2011-05-27: JP Morgan Raises PT On Emergent BioSolutions To \$35

Financial news for EBS dated on 2011-05-26: Emergent Biosolutions Ticks over 15% Higher on Anticipated Government Agreement

Financial news for EBS dated on 2011-05-09: Top Percentage Gainers and Losers as of 12pm 5/09/11 (SCEI, FFHL ROSE, SMI, DTG, HTZ, SYU, CERS, LFT, ZRAN, OXGN, MOBI, GKK, EBS, TSN)

Financial news for EBS dated on 2011-05-05: Biotech/ Biodefense Sector Trading Alert

Financial news for EBS dated on 2011-05-02: U.S. Government Expands BioThrax Procurement Contract to 17.92M Doses from 14.5M Increasing Contract Value by up to \$101 Million (EBS)

Financial news for EBS dated on 2011-04-14: Biotech/ Biodefense Stock Trading Alert; Emergent Biosolutions (NYSE: EBS) Hits 52 Week High

Financial news for EBS dated on 2011-04-14: Biotech/ Biodefense Stock Trading Alert; Emergent Biosolutions (NYSE: EBS) Hits 52 Week High

Financial news for EBS dated on 2011-04-13: Emergent BioSolutions Hits 52-Week High (EBS)

Financial news for EBS dated on 2011-04-08: Biotech/ Biodefense Sector Trading Alert

Financial news for EBS dated on 2011-03-23: Biodefense Stocks/ Homeland Defense Stock Alert; Dynasil Corporation trading at \$6.26, up 2.50 (66.49%)

Financial news for EBS dated on 2011-03-22: Biodefense Stocks Snapshot

Financial news for EBS dated on 2011-03-11: J.P. Morgan Comments On Uneventful 4Q10 Results For Emergent BioSolutions

Financial news for EBS dated on 2011-02-25: Emergent BioSolutions Announces that European Parliament Expresses Support for Rapid Development of New TB Vaccine

Financial news for EBS dated on 2011-01-13: Zacks #5 Rank Additions for Thursday - Tale of the Tape

Financial news for EBS dated on 2011-01-13: Zacks #5 Rank Additions for Thursday - Tale of the Tape

Financial news for EBS dated on 2010-12-30: First California to Acquire Division of Palm Desert National Bank

Financial news for EBS dated on 2010-12-27: Emergent BioSolutions Starts Phase I Clinical Trial for Third Generation Anthrax Vaccine

Financial news for EBS dated on 2010-10-15: Can Pharmathene Go From \$2 To \$20? Seeking Alpha's James Altucher Investigates

Financial news for EBS dated on 2010-10-08: WellPoint Appoints Lori Beer as Executive Vice President

Financial news for EBS dated on 2010-09-17: Emergent BioSolutions Awarded Contract Valued at up to \$186.6 Million (EBS)

Financial news for EBS dated on 2010-09-08: Accenture Clinches Defense Order - Analyst Blog

Financial news for EBS dated on 2010-09-08: Trubion Pharmaceuticals Announces Early Termination of HSR Waiting Period

Financial news for EBS dated on 2010-09-08: Emergent BioSolutions Announces Early Termination of HSR Waiting Period for Its Acquisition of Trubion Pharmaceuticals

Financial news for EBS dated on 2010-08-18: Trubion Pharma Trims Loss - Analyst Blog

Financial news for EBS dated on 2010-08-13: Benzinga's Top Pre-Market NASDAQ Gainers (UNCA, PRXI, TRBN, VECO)

Financial news for EBS dated on 2010-06-03: Top 5 Small-Cap Stocks In The Biotechnology Industry With The Highest Return On Equity (OMPI, MRX, AOB, EBS, SSRX)

Financial news for EBS dated on 2010-05-06: Benzinga's Top Downgrades (SWM , COGT, PRO, CNP, EBS)

Financial news for EBS dated on 2010-01-05: Should You Buy the Big Winners of 2009?

Financial news for EBS dated on 2009-12-14: The Forex Marketplace

Financial news for EBS dated on 2009-12-04: J.P.Morgan's View on Emergent BioSolutions Inc. (NYSE: EBS)

Financial news for EBS dated on 2009-10-09: Cramer talks about AEPI, GRA, TKLC, LVS, WYNN, EBS